Cargando…

PI3K inhibition sensitizes EGFR wild-type NSCLC cell lines to erlotinib chemotherapy

Tyrosine kinase inhibitors (TKIs) bring significant benefits for patients with cancers harboring epidermal growth factor receptor (EGFR) mutations. However, after treatment for a certain period, most patients ultimately acquire resistance. Numerous studies indicated that PI3K has an important role i...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xin, Wang, Xiaowen, Zhu, Hongge, Gu, Guomin, Zhan, Yiyi, Liu, Chunling, Sun, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678642/
https://www.ncbi.nlm.nih.gov/pubmed/33235618
http://dx.doi.org/10.3892/etm.2020.9441